Collaboration, License, and Other Agreements (Tables)

6 Months Ended

Jun. 30, 2022

Table Text Blocks

Schedule of revenue attributable to transactions from collaboration and license arrangements

	Three Months Ended				Six Months Ended
	June 30,				June 30,
Collaborative Arrangements Revenue	2022		2021		2022		2021
Linaclotide Collaboration and License Agreements:
AbbVie (North America)	$	95,061	$	101,038	$	189,962	$	187,537
AbbVie (Europe and other)		528		574		1,138		1,174
AstraZeneca (China, including Hong Kong and Macau)		148		200		340		410
Astellas (Japan)		500		570		1,023		1,066
Co-Promotion and Other Agreements:
Alnylam (GIVLAARI)		585		596		1,408		1,052
Other		409		408		889		812
Total collaborative arrangements revenue	$	97,231	$	103,386	$	194,760	$	192,051
Sale of API
Linaclotide Agreements:
AstraZeneca (China, including Hong Kong and Macau)	$	—	$	576	$	—	$	597
Other		—		69		—		228
Total sale of API	$	—	$	645	$	—	$	825

AbbVie

Table Text Blocks

Schedule of revenue attributable to transactions from collaboration and license arrangements

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2022		2021		2022		2021
Collaborative arrangements revenue related to sales of LINZESS in the U.S.	$	94,452	$	100,307	$	188,771	$	186,256
Royalty revenue		609		731		1,191		1,281
Total collaborative arrangements revenue	$	95,061	$	101,038	$	189,962	$	187,537